Liver Transplantation for Neuroendocrine Tumors: What Have We Learned?

Abstract

Neuroendocrine tumors are slow-growing tumors and associated with prolonged overall survival even in the presence of untreated liver metastases. The presence of liver metastases may be responsible for severe symptoms with impairment of quality of life. Liver resection has been proposed to achieve better symptom control and/or improve overall survival, but this concerns less than 20% of patients with liver metastases. In addition, the chance to be really cured after liver resection is around 40%, which prompts consideration of liver transplantation as the only potential curative treatment. Time has come to move beyond the traditional debate around the best candidates and prognostic factors for liver transplantation. This review gives the opportunity to discuss new insights: (1) outcome of liver transplantation for neuroendocrine liver metastases as compared with hepatocellular carcinoma, (2) outcome of salvage liver transplantation as a secondary procedure after surgical resection of neuroendocrine liver metastases, (3) outcome of palliative liver transplantation for neuroendocrine liver metastases, and (4) the chance to be cured after liver transplantation for neuroendocrine liver metastases.

Keywords

liver transplantation - neuroendocrine tumors - liver metastases

• References

• 1 Yao JC, Hassan M, Phan A. , et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
• 2 Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol 2011; (e-pub ahead of print) DOI: 10.4061/2011/154541.
• 3 Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18 (03) 145-149
• 4 Frilling A, Modlin IM, Kidd M. , et al; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15 (01) e8-e21
• 5 Bagante F, Spolverato G, Merath K. , et al. Neuroendocrine liver metastasis: the chance to be cured after liver surgery. J Surg Oncol 2017; 115 (06) 687-695
• 6 de Mestier L, Lardière-Deguelte S, Brixi H. , et al. Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors. Neuroendocrinology 2015; 101 (02) 105-111
• 7 De Vreede I, Steers JL, Burch PA. , et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6 (03) 309-316
• 8 Le Treut YP, Grégoire E, Belghiti J. , et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008; 8 (06) 1205-1213
• 9 Le Treut YP, Grégoire E, Klempnauer J. , et al; For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257 (05) 807-815
• 10 Nguyen NT, Harring TR, Goss JA, O'Mahony CA. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol 2011; 2011: 742890
• 11 Gedaly R, Daily MF, Davenport D. , et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146 (08) 953-958
• 12 Sher LS, Levi DM, Wecsler JS. , et al. Liver transplantation for metastatic neuroendocrine tumors: outcomes and prognostic variables. J Surg Oncol 2015; 112 (02) 125-132
• 13 Mazzaferro V, Sposito C, Coppa J. , et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 2016; 16 (10) 2892-2902
• 14 Nobel YR, Goldberg DS. Variable use of model for end-stage liver disease exception points in patients with neuroendocrine tumors metastatic to the liver and its impact on patient outcomes. Transplantation 2015; 99 (11) 2341-2346
• 15 Fan ST, Le Treut YP, Mazzaferro V. , et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB 2015; 17 (01) 23-28
• 16 Richards-Taylor S, Tilley C, Jaynes E. , et al. Clinically significant differences in Ki-67 proliferation index between primary and metastases in resected pancreatic neuroendocrine tumors. Pancreas 2017; 46 (10) 1354-1358
• 17 Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992; 112 (06) 1024-1031 , discussion 1031–1032
• 18 Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20 (07) 908-914 , discussion 914–915
• 19 Chamberlain RS, Canes D, Brown KT. , et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000; 190 (04) 432-445
• 20 Ejaz A, Reames BN, Maithel S. , et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB 2018; 20 (03) 277-284
• 21 Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery 2018; 163 (01) 218-225
• 22 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017; 14 (04) 203-217